Monday, March 18, 2013

Propolis Component May Help Treat Advanced Prostate Cancer


Caffeic Acid Phenethyl Ester as an Adjuvant Therapy for Advanced Prostate Cancer
Med Hypotheses, 2013 Feb 22. pii: S0306-9877(13)00075-3
Prostate cancer is the second most frequently diagnosed cancer of men. Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, the majority of prostate cancer patients receiving the androgen ablation therapy will ultimately develop recurrent castration-resistant tumors within 3years.
Chemotherapy shows little effect on prolonging survival for patients with metastatic hormone-refractory prostate cancer. More than 80% of prostate tumors acquire mutation or deletion of tumor suppressor phosphatase and tensin homolog (PTEN), a negative regulator of PI3K/Akt signaling. Caffeic acid phenethyl ester (CAPE) is a strong antioxidant extracted from honeybee hive propolis. Recent studies indicate that CAPE treatment suppresses tumor growth and Akt signaling in human prostate cancer cells. Combined treatments of CAPE with chemotherapeutic drugs exhibit synergistic suppression effects. Pharmacokinetic studies suggest that intraperitoneal injection of CAPE at concentration of 10mg/kg is not toxic.
CAPE treatment sensitizes cancer cells to chemotherapy and radiation treatments. In addition, CAPE treatment protects therapy-associated toxicities in animal models. We therefore propose that administration of CAPE is a potential adjuvant therapy for patients with castration-resistant prostate cancer.

3 comments:

cancer alternative treatments said...

That's nice. There are a lot of alternative treatment for cancer that's available today. A patient may choose what to get and how he or she wants to get it. Thanks for sharing!

cancer alternative treatments said...

That's nice. There are a lot of alternative treatment for cancer that's available today. A patient may choose what to get and how he or she wants to get it. Thanks for sharing!

Milind said...

Caffeic acid phenethyl ester, a Nrf2 inducer, may, like all Nrf2 inducers, enable the survival of cancerous cells. Comment?